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The Latent Membrane Protein 1 of the Epstein–Barr virus is required for human B lymphocyte immortalization and functions as a
constitutively activated member of the TNF-receptor family, through recruitment of TRAFs and TRADD molecules on its Carboxy-terminal
domain, leading to the activation of NF-κB and AP1 transcription factors. The formation of the signaling complexes requires LMP1
oligomerization, a role assigned to the membrane-spanning domains of the molecule. There is, however, increasing evidence that these membrane-
spanning domains are not only confined to oligomerization but play a direct role in downregulation of promoter activity and cytostasis. Here, we
describe a new inhibitory activity which is effective on viral or cellular promoters (even the endogenous ones), requires only membrane-spanning
domains 3–4 or 5–6 and is neither associated with cytostasis nor with apoptosis.
© 2006 Elsevier Inc. All rights reserved.Keywords: EBV; LMP1; Membrane-spanning domains; Promoters; CytostasisIntroduction
Epstein–Barr virus (EBV) is an ubiquitous B-lymphotropic
γ-herpes virus which is thought to latently infect more than 95%
of the world's adult population. EBV is the causative agent of
infectious mononucleosis but is also associated with several
malignant diseases of epithelial or lymphoid origin including
Burkitt's lymphoma (BL), Hodgkin's disease (HD), T cell
lymphoma, post-transplant lymphoproliferative disorders, gas-
tric carcinoma and undifferentiated nasopharyngeal carcinoma
(NPC) (Young and Rickinson, 2004). In vitro, EBV efficiently
infects human B lymphocytes and confers them the capacity to
grow under culture conditions for a greatly extended period of
time, during which some will become truly immortalized
lymphoblastoid cell lines (LCL) by reactivating cellular
functions, particularly telomerase activity (Sugimoto et al.,
2004). Despite the fact that the viral genes necessary for in vitro
B lymphocyte immortalization have been identified (Kieff and
Rickinson, 2001), the role of EBV in malignant transformation⁎ Corresponding author. Fax: +335 62 74 45 58.
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doi:10.1016/j.virol.2006.02.010is far from being understood and very likely varies from one
tumor to the next, as does the pattern of viral gene expression.
However, analysis of the transforming potential of viral genes
expressed in different tumors early identified the BNLF1 gene
as an oncogene, as its ectopic expression in rodent cells induced
their malignant transformation and conferred them the ability to
form tumors in nude mice (Baichwal and Sugden, 1988; Wang
et al., 1985). Moreover, transgenic mice expressing the BNLF1
gene in skin or in B lymphocytes develop skin hyperplasia
(Wilson et al., 1990) and B lymphoma, respectively (Kulwichit
et al., 1998). The BNLF1 gene thus displays all the
characteristics of an oncogene and is expressed in several
types of latency to produce an integral membrane protein:
LMP1. LMP1 is composed of cytoplasmic N terminal and C
terminal domains (respectively 24 and 200 amino acids long in
the B95-8 strain), separated by 160 amino acids divided
between 6 hydrophobic transmembrane (TM) segments
connected by short extramembrane loops (Eliopoulos and
Rickinson, 1998). LMP1 expression in epithelial or lymphoid
cells results in upregulation of numerous cellular proteins,
including MHC class II molecules (Zhang et al., 1994),
adhesion molecules such as ICAM1/CD54 (Wang et al.,
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(Henderson et al., 1991) and A20 (Laherty et al., 1992),
receptors such as EGF-R (Miller et al., 1995), and many other
factors involved in tumor metastasis such as cyclooxygenase-2
(Murono et al., 2001) and metalloproteinases (Takeshita et al.,
1999). LMP1 spontaneously oligomerizes in membrane lipid
rafts, which appears to be necessary for the LMP1 C-terminal
domain to recruit cellular factors normally associated to the
TNF-α receptor (TRAFs) and other members of this family (IL-
1R, CD30, CD40). This recruitment is mediated by the C-
terminal Activating Regions (CTARs), either directly via the
CTAR1 located just proximal to the cell membrane (amino acids
194–231) or via the TNF receptor-associated death domain
(TRADD) which binds to the CTAR2 (corresponding to C-
terminal amino acids 351–386) (Eliopoulos and Young, 2001).
The recruitment of TRAFs, which are normally associated with
molecules of the TNF-R family, suggests that LMP1 mimics a
ligand-independent, constitutively activated receptor function-
ally related to this family (Lam and Sugden, 2003). The
demonstration that intracellular C-terminal regions of LMP1
and CD40 are interchangeable is evidence that they belong to
the same functional family despite the fact that they share very
little protein homology (Gires et al., 1997). The binding of
TRAFs (and possibly other as yet unidentified factors) to LMP1
initiates cascades of phosphorylations resulting in the activation
of numerous transcription factors including NF-κB (Ham-
marskjold and Simurda, 1992), AP-1 (Kieser et al., 1997), ATF2
(Eliopoulos et al., 1999) and certain STATs (Chen et al., 2003;
Gires et al., 1999), which likely accounts for all the described
LMP1 induced cellular modifications.
In contrast with these previous observations, it has been
more recently described that LMP1 is able to inhibit the activity
of several EBV promoters, including its own promoter and
EBNA Cp. It is probable that numerous cellular promoters are
sensitive to this inhibition, as LMP1 expression was noted to
significantly decrease cellular protein synthesis (Sandberg et al.,
2000). It was hypothesized that this general inhibition could be
the necessary counterpart allowing the cell to overcome the
wide activating properties of LMP1, which in the long term
could be heavily detrimental. This LMP1-dependent inhibition
of protein synthesis also offers a very logical explanation for the
reported toxicity of overexpressed LMP1 (Hammerschmidt et
al., 1989), and for more recent reports indicating that LMP1
expression blocks cell division and induces long-lasting
cytostasis (Coffin et al., 2001, 2003; Floettmann et al., 1996;
Kaykas and Sugden, 2000). However, these later observations
are difficult to reconcile with the oncogenic properties of LMP1,
whose expression has been widely documented in fast-growing
tumors, including the vast majority of EBV positive HD and
NPC (Kieff and Rickinson, 2001). Moreover, an elegant study
of Kilger et al. (1998) suggests that LMP1 is necessary for the
proliferation of EBV-immortalized B lymphocytes, in which it
could play the same role as the activated CD40 receptor. The
reasons for these observed opposite effects of LMP1 expression
are not clear and the use of different cellular models does not
account for all the observed discrepancies, as conflicting results
have been obtained by Floettmann et al. (1996) using the DG75B cell line. LMP1 thus appears to be a very complex regulator
able to activate numerous signaling pathways and to
concomitantly inhibit gene expression from a large body of
cellular promoters.
These paradoxical effects prompted us to investigate the
effects of LMP1 on various natural complex promoters in
transiently transfected DG75 cells. We chose to focus on widely
used ubiquitous viral or cellular promoters believed to be
expressed in most cells, to be poorly sensitive to the cellular
context and containing cis-acting elements for transcription
factors activated by LMP1: the immediate early promoter of the
human cytomegalovirus (IE-CMV) (Lee et al., 2004), the early
promoter of the Simian Virus 40 (E-SV40) (Tabakin-Fix et al.,
2004), the promoter controlling the expression of the protein
elongation factor 1α gene (EF-1α) (Wakabayashi-Ito and
Nagata, 1994) and the promoter of the Glyceraldehyde-3-
phosphate dehydrogenase gene (GAPDH). In this paper, we
report that LMP1 inhibits the activity of several (but not all)
promoters of viral or cellular origin and that a mutant LMP1
lacking the C-terminal region retains the full inhibitory capacity
of the wild-type protein. Using a battery of mutants with various
combinations of TM domains, we were able to map the
involved region to the TM domains 3–4 and 5–6, without
implication of the TM domains 1–2. Interestingly, we could
exclude the trivial hypothesis that this LMP1-induced inhibition
resulted from apoptosis of the transfected cells. Moreover,
under our conditions leading to inhibition of gene expression,
LMP1 does not induce cytostasis and LMP1-positive DG75
cells continued to proliferate at the same rate as cells transfected
with a control gene. We thereby describe a possibly new effect
of LMP1, inhibiting gene expression from some but not all
promoters, without affecting cell viability or proliferation.
Results
LMP1 inhibits the activity of some but not all promoters
For the sake of simplicity and according to Sandberg et al.,
we define promoter activity as the sum of all cellular processes
required to generate a reporter signal in our transfection
experiments. It has been shown that LMP1 was able to inhibit
gene expression from the EBV Bam-C promoter or from the
BNLF1 gene promoter and that this inhibition was associated
with a general decrease in protein synthesis in BJAB cells
(Sandberg et al., 2000). As LMP1 is also known to activate
several transcription factors, it was of interest to study its effect
on natural complex promoters containing response elements for
different transcription factors, some of which able to be
activated by LMP1. Promoters from viral (IE-CMV) or cellular
(EF-1α, GAPDH) origins were cloned in front of the firefly
luciferase gene to generate pCin-Luc, pEF-Luc or pGAPDH-
Luc, respectively. The pGL3 vector (Promega), containing the
same luciferase gene, was used to test the E-SV40 promoter.
These constructs were independently cotransfected in DG75
cells with increasing amounts of an expression vector for the
B95-8 BNLF1 gene (pCin-LMP1) and the empty vector pCi-
neo was introduced to equalize plasmid quantities in all
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LMP1 but expressing the EGFP gene instead of the BNLF1
gene (pEGFP-N3, Clontech). This choice resulted from
preliminary observations indicating that different expression
vectors, regardless of the gene they contained, partially
inhibited in a nonspecific way luciferase production when
cotransfected with the luciferase expression vector pCin-Luc in
DG75 cells (Fig. 1A). This inhibition, which was never
observed when an empty vector was cotransfected with pCin-
Luc, likely results from competition between the plasmids or
their derived mRNAs for transcription and/or translation factors
present in limiting concentrations. However, in addition to the
non specific inhibition observed following expression of any
gene, LMP1 always induced a stronger and specific inhibition
of luciferase production (Fig. 1A). In order to only evaluate this
specific LMP1-induced inhibition in all subsequent experi-
ments, the luciferase activity measured in the presence of
increasing amounts of the expression vectors for LMP1 or itsFig. 1. Effect of LMP1 on the activity of the IE-CMV, E-SV40 and EF-1α promoters. (
vector and the indicated quantities of pCi-neo (open bars), pEGFP-N3 (grey bars) or p
quantities in all experiments. The luciferase activity induced by the pCin-Luc vector i
the IE-CMV promoter and used to calculate relative activity of this promoter in t
experiment as in panel A except that the relative IE-CMV promoter activity is the per
indicated amounts of the pCin-LMP1 vector as compared to luciferase activity in th
100%. (C) Similar experiment as in panel B but with the pEF-Luc reporter vector ins
promoter. (D) Similar experiment as in panel B but with the pGL3 reporter plasmid ins
promoter. (E) Activation of the NF-κB pathway measured by the increase in the quanti
reporter plasmid and 4 μg of the indicated vectors. (F) Western blot detection of LMPderivatives was normalized against the luciferase activity
detected in the presence of identical quantities of an expression
plasmid for a neutral gene (EGFP or β-galactosidase),
considered as 100%. In these conditions, the effect of increasing
amounts of LMP1 on various promoters was analyzed and is
shown in Figs. 1B, C and D. Interestingly, LMP1 induced a
strong and specific inhibition of the IE-CMV and EF-1α
promoters (and of the GAPDH promoter, result not shown)
when the E-SV40 promoter appeared completely insensitive to
this inhibition. In order to make sure that this inhibition did not
result from unexpected effects possibly induced by large
quantities of LMP1, we verified the activation of the NF-κB
signaling pathway using the pNF-κB-Luc reporter plasmid,
containing 4 NF-κB binding sites originating from the κ light
chain enhancer element. As expected, the largest quantity (4 μg)
of pCin-LMP used in the previous tests induced a robust and
specific 10-fold increase of the luciferase activity over the
controls (Fig. 1E). Using Western blot analysis, we also verifiedA) One million DG75 cells were electroporated in the presence of 2 μg pCin-Luc
Cin-LMP1 (black bars). The empty vector pCi-neo was added to equalize DNA
n the presence of 4 μg of the pCi-neo empty vector was fixed as 100% activity of
he presence of increasing amounts of pEGFP-N3 or pCin-LMP1. (B) Similar
centage luciferase activity induced by the pCin-Luc vector in the presence of the
e presence of identical amounts of the control pEGFP-N3 vector, considered as
tead of pCin-Luc in order to test the effect of LMP1 on the activity of the EF-1α
tead of pCin-Luc in order to test the effect of LMP1 on the activity of the E-SV40
ty of luciferase produced in 106 DG75 cells cotransfected with 2 μg pNF-κB-Luc
1 in DG75 cells transfected with the indicated amounts of the pCin-LMP1 vector.
384 S. Narbonnet, B. Mariamé / Virology 350 (2006) 381–393that transfection of increasing amounts of pCin-LMP1 plasmid
effectively resulted in increasing amounts of LMP1 in the cells
(Fig. 1F). To rule out the unlikely possibility that LMP1 could
directly interfere with luciferase to block its activity, similar
experiments were also performed using the pCin-βgal vector
(containing the β-galactosidase gene as a reporter instead of the
luciferase gene) and identical results were obtained (results not
shown). All these results indicate that LMP1 is able to
specifically inhibit gene expression from several different but
not all promoters. As the IE-CMV, EF-1α and GAPDH
promoters were similarly inhibited by LMP1, only one
promoter was analyzed in most of the following experiments,
which were performed with the pCin-Luc reporter.
LMP1 inhibits the activity of the endogenous EF-1a and
GAPDH promoters
In order to check the relevance of these transfection
experiments, we tested the effect of LMP1 expression on the
endogenous EF-1α and GAPDH gene promoters. DG75 cells
were cotransfected with pSVK3-EGFP (a vector driving
expression of the GFP under the control of the E-SV40
promoter shown to be insensitive to LMP1-induced inhibition;
Fig. 1D) in addition to pCin-LMP1 or pCin-β gal. Forty hours
later, cells were sorted according to their GFP status using an
Epics Altra cell sorter. RNA was extracted from GFP-positive
populations. After cDNA synthesis, we checked by RT-PCR
that the BNLF1 gene was expressed only in cells transfected
with pCin-LMP1 and positive for GFP (results not shown).
Then, using a semi-quantitative RT-PCR assay, the levels of EF-
1α and GADPH mRNAwere compared in β-galactosidase- and
in LMP1-positive cells. As shown in Fig. 2, EF-1α and GAPDH
mRNA levels were slightly albeit significantly decreased in
LMP1-expressing cells as compared to β-galactosidase-expres-
sing cells.Fig. 2. Effects of LMP1 on the EF-1α and the GAPDH endogenous promoters. Ten in
of pSVK3-EGFP vector and 2 μg of pCin-βgal or pCin-LMP1 vectors. Forty hours
extracted from each population, converted into cDNAs which were used as templat
Amplification products were analyzed on 2% agarose gels and quantified using the G
performed on cDNA prepared from GFP-positive cells expressing β-galactosidase (la
14 RT-PCR cycles (lanes 1 and 2) or 16 RT-PCR cycles (lanes 3 and 4). The results ar
Quantification of GAPDH and EF-1α RT-PCR products from GFP-positive, β-gala
LMP1-expressing cells (black bars). Analysis was performed in both cases on RT-
(GAPDH) or three (EF-1α) independent experiments (*P < 0.05 by Student's t testThe carboxy-terminal domain is dispensable for the inhibitory
activity of LMP1
To test whether this inhibition was dependent on signaling
pathways classically activated by LMP1, we performed similar
experiments with an LMP1 derivative corresponding to the first
190 amino acids of the wt protein and thus lacking the complete
intracytoplasmic C-terminal domain (ΔCT-LMP1). As negative
and positive controls, we used the β-galactosidase and the wt
BNLF1 genes, and results show that LMP1 and its ΔCT-LMP1
derivative inhibit the IE-CMV promoter activity with equal
efficacy (Fig. 3A), indicating that the LMP1 amino-terminal and
TM domains alone suffice to confer complete inhibitory
capacity to the protein.
LMP1 inhibits the IE-CMV promoter activity through its
transmembrane domains 3–4 or 5–6
Several groups have reported that all TM domains of LMP1
are not equivalent and that the TM domains 1–2 are particularly
implicated in lipid raft targeting (Yasui et al., 2004). This
prompted us to try to map the region of LMP1 involved in this
inhibition. For this purpose, we generated a series of mutants
lacking one pair of TM domains but retaining normal amino-
and carboxy-terminal extremities: N-TM3456-C, lacking TM
domains 1 and 2 (corresponding to amino acids 24 to 74), N-
TM1256-C, lacking amino acids 75 to 133, and N-TM1234-C,
lacking amino acids 133 to 190. Cotransfections of these
mutants in DG75 cells with the pCin-Luc reporter plasmid
showed that they all retained the full inhibitory capacity of the
wt LMP1, suggesting that this inhibitory capacity is not
associated with a single pair of TM domains (Fig. 3B). We
then constructed a second series of similar LMP1 derivatives,
but with each retaining only one single pair of TM domains: N-
TM12-C, lacking TM domains 3, 4, 5 and 6 (from amino acidsdependent electroporations were performed on one million DG75 cells with 2 μg
after transfection, cells were sorted according to GFP expression. RNAs were
es in semi-quantitative RT-PCR assays targeting EF-1α or GAPDH sequences.
eneTools software (Syngene). (A) EF-1α or GAPDH semi-quantitative RT-PCR
nes 1 and 3) or LMP1 (lanes 2 and 4). Amplification products were obtained after
e representative of two (GAPDH) or three (EF-1α) independent experiments. (B)
ctosidase-expressing cells (considered as 100%, open bars) and GFP-positive,
PCR products obtained after 14 cycles. Presented values are averages of two
).
Fig. 3. Inhibition of the IE-CMV promoter by an LMP1 mutant lacking the carboxy-terminal region and identification of the membrane-spanning domains involved in
the LMP1-induced inhibition of the IE-CMV promoter activity. (A) One million DG75 cells were electroporated with 2 μg of the pCin-Luc reporter plasmid and the
indicated amounts of plasmids expressing a control gene (β-galactosidase, open bars), the wild-type LMP1 (black bars) or itsΔCT derivative (grey bars). Twenty-four
hours after transfection, cells were lysed and luciferase quantified. The relative IE-CMV promoter activity is expressed as the percentage of luciferase activity detected
in the presence of LMP1 or its DCT-LMP1 derivative as compared to luciferase activity produced in the presence of identical quantities of the control vector,
considered as 100%. (B) One million DG75 cells were electroporated in the presence of 2 μg of the pCin-Luc reporter plasmid and 1 or 4 μg of pCin-βgal vector as the
control, pCin-LMP1 or LMP1 mutants lacking one pair of TM domains: N-TM3456-C, N-TM1256-C and N-TM1234-C. The relative IE-CMV promoter activity was
calculated as in panel A. (C) Similar experiment as in panel B excepted that LMP1 mutants with a single pair of TM domains were tested: N-TM12-C, N-TM34-C and
N-TM56-C. (D) Similar experiment as in panels B and C except that electroporations were performed in the presence of pSVK3-EGFP and that results were
normalized on the percentages of GFP positive cells in each transfection. Effects of N-TM12-C (horizontal stripes), full-length LMP1 (black bars) and N-TM3456-C
(oblique stripes) were compared to the β-galactosidase control (empty bars). (E) Western blot analysis of LMP1 or derivatives expression in the lysates of cells
transfected with 4 μg of plasmids and used to generate the results presented in panel C. Detection was performed using the S12 anti-LMP1 monoclonal antibody.
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(amino acids 24 to 74 and 133 to 190) and N-TM56-C, lacking
amino acids 24 to 133. When analyzed for their ability to inhibit
luciferase expression from the pCin-Luc vector, these mutants
revealed different behaviors: while N-TM34-C and N-TM56-C
seemed to inhibit as well as the wt LMP1, N-TM12-C appeared
significantly impaired in its ability to inhibit luciferase
production from the pCin-Luc vector (Fig. 3C). A similar
experiment was again performed with wt LMP1 or with mutantsN-TM3456-C and N-TM12-C, but including the pSVK3-EGFP
vector in order to normalize the results on the fractions of GFP-
positive cells. As shown in Fig. 3D, results are nearly identical
to those obtained without normalizing on GFP expression (Fig.
3C). We verified expression of the different mutants in parallel
with the lysates used for luciferase expression assays and all
appeared to be expressed at similar or higher levels than the wt
LMP1, suggesting that the observed difference in inhibitory
capabilities between the different mutants could not be
Fig. 4. Kinetics of the LMP1-induced inhibition of the IE-CMV. Three aliquots of 106 DG75 cells were electroporated with 2 μg of the pCin-Luc reporter plasmid and
2 μg of the indicated plasmids, subsequently pooled and cultivated together. Duplicate aliquots corresponding to 2.5 × 105 initial cells were harvested 3, 9, 20 and 48 h
after transfection, lysed in 100 μL 1× CCLR and analyzed for luciferase activity as described. (A) Time course analysis of the luciferase activity present in the lysates of
cells transfected with the indicated plasmids, expressed as light units. (B) Same as panel A but expressed as relative IE-CMV promoter activity calculated by
comparison with the luciferase activity in the presence of the pCin-βgal control plasmid, considered as 100% activity at each time point. (C) Western blot analysis of
LMP1 or derivative expression (excepted ΔCT-LMP1) in the lysates used to generate the results presented in panels A and B. Detection was performed as in Fig. 3C.
(D) Western blot analysis as in panel C but revealed with the AC15 anti-β-actin monoclonal antibody.
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strongly suggest that molecules containing normal amino- and
carboxy-terminal domains and either the TM segments 3–4 or
the TM segments 5–6 retain complete inhibitory capacity, while
the TM domains 1 and 2 do not seem to be significantly
involved in this activity.
Kinetic analysis of the LMP1 inhibitory activity
In order to characterize the kinetics of this inhibition, we
cotransfected in DG75 cells the pCin-Luc reporter plasmid with
expression vectors for the β-galactosidase gene, for LMP1 or
for its ΔCT-LMP1, N-TM3456-C or N-TM12-C derivatives.
Aliquots from the different experiments were taken after
various periods of time and analyzed for expression of
luciferase and LMP1 or its derivatives. As shown in Figs. 4A
and B, inhibition of luciferase production by LMP1 and its
inhibitory derivatives was observed as early as 9 h post-
transfection. Moreover, luciferase activity increased up to 20 h
in cells cotransfected with the β-galactosidase gene or the N-
TM12-C mutant, but displayed a marked decrease at this time
point in cells expressing the wt LMP1 or its inhibitory
derivatives. The difference in luciferase activity was still
evident 48 h after transfection when cells resumed protein
synthesis and likely proliferation as shown by a huge increase
in actin synthesis at this time. Western blot analysis showedthat LMP1 and its derivatives were not all expressed at
identical levels during the course of this experiment (Figs. 4C
and D). N-TM3456-C in particular showed much higher
expression than the others. However, N-TM12-C and the wt
LMP1 were expressed at similar levels (at least from the 20 h
time point), suggesting that their different behaviors were not
the consequence of differential expression.
Inhibition of gene expression does not induce cytostasis
Kaykas et al. have published that expression of an LMP1
derivative containing only the amino-terminal and the mem-
brane-spanning domains induced cytostasis. To investigate a
possible relationship between the herein described inhibition of
different promoters and cytostasis, we decided to follow the
proliferation of DG75 cells transfected with either the β-
galactosidase gene, LMP1, or various derivatives, using the Cell
Tracker Orange™ CMTMR. This fluorescent dye irreversibly
binds to thiol groups inside the cell and is diluted upon cell
division, allowing cytofluorimetric monitoring of cell prolifer-
ation. As controls for proliferating and nonproliferating cells,
we used electroporated, CMTMR-stained cells cultivated in
normal medium or in the presence of mitomycin C, which
blocks cell division. As shown in Fig. 5A, CMTMR labeling
decreased only in untreated, dividing cells. In order to separate
transfected from nontransfected cells in these experiments, we
Fig. 5. Effect of LMP1 or derivatives on DG75 cell proliferation and apoptosis. (A) One million DG75 cells were stained with CMTMR Cell Tracker Orange
(Molecular Probes), electroporated without adding any plasmid and cultivated in normal medium (solid grey line) or in medium containing 10 μg/mL mitomycin C to
block cell division (solid black line, filled histogram). Forty-eight hours later, cells were analyzed for CMTMR fluorescence using an Epics XL4C FACS. Decrease of
the fluorescence in the FL2 channel indicates that cells not treated with mitomycin C normally divide, when mitomycin C treated cells do not. These populations are
used as proliferating (solid grey line) and nonproliferating (solid black line, filled histogram) controls for the next experiments together with nonstained cells (dotted
line). (B) One million DG75 cells were stained with CMTMR Cell Tracker Orange, electroporated with 4 μg pSVK3-EGFP and 2 μg pCi-neo plasmids and analyzed
48 h later for GFP fluorescence (FL1). CMTMR labeling (FL2) was subsequently analyzed on GFP positive (R3, black bold line) and GFP negative (R2, black thin
line). (C) Similar experiment as in panel B except that the pCi-neo empty vector was replaced by the indicated vectors expressing β-galactosidase, LMP1,ΔCT-LMP1,
N-TM3456-C or N-TM12-C mutants. (D) Equal quantities (2 × 105) of GFP-positive and -negative cells from the experiments described in panel C were purified using
a High Speed cell sorter Epics Altra, lysed and analyzed by Western blot for LMP1 or derivative expression, for β-actin and for the cleavage of PARP using,
respectively S12, AC-15 and C2-10 monoclonal antibodies.
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pSVK3-EGFP plasmid, bringing the GFP expression under
the control of the LMP1-unsensitive E-SV40 promoter. Forty-
eight hours after transfection, GFP-positive and -negative cells
were analyzed by FACS for CMTMR fluorescence. As shown
in Fig. 5B, when cells were electroporated in the presence of
pSVK3-EGFP and the empty pCi-neo vector, the GFP-positive
and -negative cells divided at the same rate as the control cells
not treated with mitomycin C. Fig. 5C illustrates the
proliferation of GFP positive cells expressing β-galactosidase,LMP1, ΔCT-LMP1, N-TM3456-C or N-TM12-C derivatives,
as compared to the corresponding GFP-negative cells from each
experiment. These results strongly suggest that expression of
LMP1 or its inhibitory derivatives has no effect on cell division
and does not induce cytostasis in this cellular model. In order to
validate this approach and the fact that the GFP-positive cells
truly were the cells transfected with the tested plasmids, we
sorted the GFP-positive and -negative cells from the same
experiments using the Epics Altra cell sorter. The same number
of cells from both populations was lysed and analyzed in
388 S. Narbonnet, B. Mariamé / Virology 350 (2006) 381–393Western blot experiments for the presence of wt LMP1 or
derivatives. As shown in Fig. 5D, large quantities of LMP1 or
derivatives were detected only in GFP-positive cells, and no
signal was observed with the S12 anti-LMP1 antibody in the
GFP-negative cells, confirming that, in these experiments,
LMP1 or derivatives were expressed at detectable levels only in
the GFP positive cell population.
LMP1 expression does not induce apoptosis
As it has been reported that expression of large quantities of
LMP1 could be toxic for cells (Hammerschmidt et al., 1989), it
was of interest to observe the apoptosis status of our LMP1
transfected cells. It is well documented that the cleavage of the
poly-(ADP-Ribose)-polymerase (PARP) p115 isoform is an
early event in apoptosis (Patel et al., 1996). Therefore, we
analyzed this cleavage in the GFP-positive and -negative cell
populations obtained from the sorting. As can be seen in Fig.
5D, the greatest quantity of PARP remained in the p115 isoform
and only minute amounts of low MW PARP isoform could be
detected in all lysates, regardless of whether they originated
from GFP-positive or -negative cells and whatever the LMP1
protein expressed. It is therefore very unlikely that LMP1 or any
of the derivatives we tested in this study were able to induce
significant apoptosis in this cellular model under the conditions
we used.
Discussion
In this study, we report that gene expression from different
natural complex promoters is inhibited in the presence of the
EBV oncoprotein LMP1 in DG75 human B cells. This effect
was mainly studied on the IE-CMV promoter, which is
considered constitutive and contains NF-κB and AP-1 response
elements, but was also observed on the cellular promoters of the
EF-1α and GAPDH genes, which are differently regulated. On
the contrary, the E-SV40 promoter, which is also sensitive to
NF-κB, completely eluded this LMP1-induced inhibition
indicating that it is not a general phenomenon. Sandberg et al.
have already published similar results, but on EBV gene
promoters, namely the Bam-Cp and the BNLF1 gene promoter.
We thus extend their observations to another herpes virus
promoter (IE-CMV) and to cellular promoters, suggesting that
this inhibition could hit enough cellular promoters to induce the
reported decrease in protein synthesis (Sandberg et al., 2000).
An LMP1 mutant deleted of the complete C-terminal region
retained the same inhibitory capacity as the wt protein,
indicating that this phenomenon was not dependent on the
already described signaling pathways activated by LMP1, but
conversely required the membrane-spanning domains and likely
involved new pathways. Using a series of mutants lacking one
or two pairs of TM domains, we were able to map more
precisely than ever before the inhibitory regions of LMP1 to the
TM domains 3–4 and 5–6, each of these pairs of TM domains
in association with normal amino- and carboxy-terminal
domains being sufficient to achieve inhibition similar to that
observed with the wt protein. Conversely, an otherwise normalLMP1 molecule containing only the TM segments 1 and 2 loses
most of its inhibitory potential. Interestingly, the N-TM12-C
mutant was still able to activate the NF-κB pathway (although
less efficiently than the wt protein), indicating that it was indeed
addressed to membranes in which it was inserted correctly
enough to mediate NF-κB activation (results not shown and
Coffin et al., 2003). It is noteworthy that TM domains 1 and 2
appear of particular importance among the TM segments as the
TM segment 1 contains the FWLY motif described to be
necessary for lipid raft targeting (Yasui et al., 2004). Moreover,
an LMP1 derivative lacking the TM domains 3, 4, 5 and 6
retains a significant ability to form signaling complexes, which
is not observed with mutants lacking the TM segments 1 and 2
(Coffin et al., 2003).
The fact that the TM domains 1 and 2 do not contribute to the
inhibitory activity of the protein, which is mainly mediated by
TM domains 3, 4, 5 and 6, is a supplementary proof that the TM
domains are not all functionally equivalent but rather mediate
specialized functions. Interestingly, when comparing the protein
sequences of TM domain pairs 1–2, 3–4 and 5–6, they all
appeared equally divergent from each other with identities of
28.6%, 21.6% and 29.6% between pairs 1–2/3–4, 1–2/5–6 and
3–4/5–6, respectively. However, comparison of TM domains 3
and 5 revealed the presence of a similar LLL/IIALW/Y motif in
both sequences. We speculate that this motif is involved in the
inhibitory capacity of the LMP1 protein and we are currently
investigating this possibility.
Higuchi et al. have shown that D1LMP1, which is naturally
initiated on the methionine 129 and contains only a short
intracytoplasmic segment, the TM domains 5 and 6 and the
complete C-terminal region, was not present in the lipid rafts,
even in the presence of the wt LMP1 (Higuchi et al., 2001). As a
consequence, it appears that D1LMP1 very poorly (or not at all)
associates with the full-length LMP1. Similar results were also
published by Gires et al. (1997) and Yasui et al. (2004). As a
consequence, it is highly probable that our N-TM56-C mutant,
which retains the full inhibitory capacity of the LMP1 wt
protein, does not oligomerize and is not present in the rafts,
suggesting that it is able to exert its inhibitory effect on various
promoters as a monomer and without requiring particular
localization. Conversely, it would be of interest to determine
whether this inhibitory capacity is only characteristic of
monomeric LMP1 or whether it is also exhibited by the
oligomerized protein.
Surprisingly, the inhibitory effect of LMP1 and its
derivatives on the IE-CMV promoter takes hold very rapidly
and is already evident as soon as 9 h after transfection. At this
time point, only minute amounts of proteins expressed from the
transfected vectors are detectable, but these quantities are
already sufficient to exert their inhibitory effect as compared to
the noninhibitory derivatives. These results suggest that this
inhibition is likely highly specific and does not depend on
competition for transcription and/or translation factors, but is
rather an intrinsic property of the molecule that is effective at
low concentration and as soon as it is produced. Furthermore,
our results presented in Figs. 1B and C show that LMP1
inhibits gene expression in a dose-dependent manner. However,
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expression of LMP1, driven by the IE-CMV promoter, induces
significant toxicity, at least in rodent cells. As all our LMP1
constructions were expressed under the control of the strong IE-
CMV promoter, it was important to rule out the trivial
possibility that LMP1-induced inhibition could simply translate
massive cell death due to apoptosis. This was unlikely in our
experiments, as the E-SV40 promoter was resistant to the
inhibitory effect of LMP1 doses which induced nearly complete
inhibition of IE-CMV, EF-1α or GAPDH promoters in the same
DG75 cells. Moreover, we observed that DG75 cells positive for
LMP1 or its inhibitory derivatives did not show any increase in
the cleavage of the poly-(ADP-ribose) polymerase (PARP), as
compared to LMP1-negative cells from the same transfection
experiment (Fig. 5D). As this cleavage is a sensitive and early
marker of apoptosis (Patel et al., 1996), these results exclude
apoptosis as an explanation for the nearly complete inhibitory
effect of LMP1 on various promoters.
Different groups have reported that expression of LMP1 or
its ΔCT derivative induces an arrest in cell growth. Coffin et al.
(2003) also reported that the TM domains 1 and 2 are
responsible for this observed cytostasis. Surprisingly enough,
in our hands, neither LMP1 nor any of its derivatives induced
cytostasis in DG75 cells. The reasons for these discrepancies are
not clear, but we find it difficult to conceive that LMP1-induced
cytostasis could be a general phenomenon. Firstly, LMP1
expression has been widely demonstrated in EBV-immortalized
B lymphocytes (LCL), where it is even required to keep them
growing (Kaye et al., 1993). Secondly, numerous EBV-
associated tumors, including Hodgkin's disease and nasopha-
ryngeal carcinoma, display LMP1 expression (Kieff and
Rickinson, 2001). Moreover, Kilger et al. reported that in
their experimental system based on conditional LMP1 expres-
sion in B lymphocytes immortalized with mini EBV plasmids,
LMP1 expression was required for cell proliferation (Kilger et
al., 1998). Possible explanations to these divergent results are
not straightforward but could perhaps be found in the use of
different techniques to evaluate cytostasis. For instance, Kaykas
and Sugden cotransfected expression plasmids for LMP1 or its
derivatives and for the β-galactosidase reporter gene, and
monitored the evolution of the transfected population as a
function of the β-galactosidase-positive cells. A decrease in the
proportion of β-galactosidase positive cells was considered
evidence of LMP1-induced cytostasis in transfected cells
(Kaykas and Sugden, 2000). The results we report herein
allow a new interpretation of these experiments, in which the β-
galactosidase gene was under the control of the IE-CMV
promoter. Therefore, as LMP1 and its so-called cytostatic
derivatives strongly inhibit this promoter, their expression
should markedly decrease the number of β-galactosidase
positive cells, without indicating cytostasis. Cytostasis was
also observed in Hep2 cells transfected with LMP1 or its ΔCT
mutant and plated in the presence of selection (Hygromycin B)
to which they became resistant due to the hygromycin
phosphotransferase gene carried by the LMP1 expression
vector. If the TK promoter driving the expression of the
resistance gene is also sensitive to the LMP1-inducedinhibition, the LMP1-positive cells will grow much more
slowly (or not at all) in selective medium. More difficult to
understand are the results of Floettmann et al. who describe the
cytostatic effect mediated by inducible LMP1 expression in
DG75 cells. However, their experiments were also performed
under selective pressure, possibly introducing some not yet
identified bias, and their LMP1-induced cytostasis was only
transient.
Whatever the reasons for these opposite results, our present
observations show that LMP1-induced cytostasis and LMP1-
induced promoter inhibition are distinct mechanisms which do
not necessarily act simultaneously. One possibility to reconcile
divergent results could be to hypothesize that LMP1-induced
inhibition is the consequence of at least two different and
additive mechanisms. The first one is the mechanism described
by Kaykas et al. and Sandberg et al., which works at high LMP1
concentration and requires TM domains 1 and 2. The second is
described herein and is effective at low LMP1 concentration
through TM domains 3–4 and 5–6 but not 1–2. These two
mechanisms possibly act at different levels as the first one
results in phosphorylation of the eIF2 α factor (Lam et al., 2004)
and likely inhibition of protein synthesis while the other seems
directly active at the transcriptional level. The major question
now concerns the mechanisms by which LMP1, located in cell
membranes, exerts its inhibition on promoters. Results obtained
with ΔCT-LMP1 indicate that the signaling pathways classi-
cally described as activated by LMP1 are not involved. This
rules out a simple hypothesis based on competition between
different signaling pathways for limiting factors like p300, as
described by Horvai et al. (1997). However, it is highly
probable that LMP1 has not yet betrayed all its secrets, and Puls
et al. (1999) have recently demonstrated that LMP1 could
activate the small GTPase Cdc42 and thus possibly the Rho
pathway downstream. Surprisingly, this activation was quite
efficiently mediated by a ΔCT-LMP1 mutant, indicating that it
was independent of LMP1 interaction with TRADD and TRAFs
factors normally associated with TNF-receptor and other
members of its family. The similarity of the LMP1 regions
required for gene expression inhibition and Cdc42 activation
prompts us to speculate that the inhibitory effect of LMP1 is
mediated by the Rho pathway and we are currently investigating
this hypothesis.
Still, the reasons why EBV has developed an LMP1molecule
endowed with such complex and divergent properties remain
obscure. On one hand, LMP1 expression triggers numerous
signaling pathways, leading to the activation of various
important transcription factors. On the other hand, the same
LMP1 under similar conditions inhibits gene expression from
various, but not all, promoters. Interestingly, when effective, this
inhibition appears to be dominant over activation. Indeed, the
IE-CMV promoter is inhibited by LMP1 when it contains
several elements responsive to NF-κB, a transcription factor
strongly activated by LMP1. The results of Sandberg et al.
suggest that the reasons for this complexity are not to be found in
differential and advantageous expression of viral versus cellular
genes, as the Bam-Cp and the BNLF1 gene promoter, which
control genes whose expression is indispensable for latency, are
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attractive explanation, is that the efficacy of LMP1 in activating
different signaling pathways could lead to a situation of general
activation and instability for the cell, close to apoptosis. The
inhibitory effect of LMP1 TM domains could therefore have
been selected in order to counterbalance this general activation
process by acting as a brake on numerous viral and particularly
cellular promoters. It is noteworthy that twomechanisms at least,
involving three distinct regions of the protein, could be involved
in the LMP1-inhibitory activity, suggesting its great importance
for the virus.
In any case, the ins and outs of the LMP1 induced inhibition
of gene expression are far from being elucidated and certainly
require further investigation. However, if LMP1 expression
truly requires a negative feed-back control mechanism neces-
sary for cell survival, it could lead to the development of
interesting new therapeutic approaches based on the inhibition
of this mechanism, whose failure could induce apoptosis in
latently infected, LMP1-expressing cells.
Material and methods
Plasmids
The expression vector for the B95-8 BNLF1 gene, pCin-
LMP1, has been constructed in two steps. First, the 5′ region of
the gene, containing the two first exons and the first intron, has
been PCR amplified from the B95-8 DNA, between oligonu-
cleotides P4-BN-S (5′-ACACGCGTTACTCTGACGTAGCC-
3′) and IE2-BN-SXb, introducing an XbaI site (5′-TTCTCTA-
GATCTTACCAAGTAAGCACCC-3′), digested with the MluI
and XbaI enzymes and cloned in the same sites of the pCi-neo
vector (Promega), previously deleted of its BglII site: this
generated pCin-E1E2. The third exon of the gene was then
amplified using primers E2-LMP1-AS (5′-GGGTGCTTACT-
TGGTAAGATCT-3′) and LMP-17-mL (5′-ATGGTAATGTC-
TAGAAGTAAAGAAAGG-3′) which introduces an XbaI site
18 nucleotides after the stop codon. This fragment was digested
with the BglII and XbaI enzymes and cloned into the
corresponding sites of pCin-E1E2, restoring a complete
BNLF1 gene and generating the pCin-LMP1 vector. The
pCin-ΔCT-LMP1 vector was directly derived from pCin-LMP1
by amplifying the complete region of interest between primers
pCi-T7, located upstream of the pCi-neo MCS (5′-GTACT-
TAATACGACTCACTATAGG-3′) and LMP27AS, starting on
codon 190 (5′-TCGTTGTCCATGGTAATACATCC-3′). This
fragment was then ligated to the phosphorylated linker STOP-
Xba (5′-TAATCTAGATTA-3′), digested with the MluI and
XbaI restriction enzymes and cloned into the corresponding
sites of the pCi-neo vector. All the TM domains mutants were
generated using a strategy (to be published elsewhere) based on
the amplification of two separate fragments which are
subsequently ligated to obtain the desired modified sequence.
This sequence is amplified again between the two external
primers and then cloned into the pCi-neo vector. The N-
TM3456-C mutant was created by ligation of the two fragments
amplified from the pCin-LMP1 vector between the primerspairs pCi-T7/LMP2318 (5′-AGAGGAGAGGGGGGGTCC-3′)
and LMP3AS (5′-GACCTTCTCTGTCCACTTGG-3′)/
cLMPXb (5′-GTCGACTCTAGAAGTAAAGAA-3′), this
later overlapping the beginning of the 3′UTR of the BNLF1
gene and pCi-neo sequence with an artificial XbaI site in
between. Fragments were ligated together after phosphoryla-
tion, the ligated product was amplified again, treated with the
restriction enzymes MluI and XbaI and finally cloned into pCi-
neo. The N-TM1256-C and N-TM1234-C mutants were
similarly obtained using primers pairs pCi-T7/LMP7466 (5′-
TCTTCTGAAGATAAAGATGATCAAAAT-3′) and LMP28S
(5′-GGTGCCACCATCTGGCAGC-3′)/cLMPXb for the N-
TM1256-C mutant and the two primers pairs pCI-T7/
LMP25AS (5′-TCGCCAGAGCATCTCCAATAAG-3′) and
LMP24S (5′-CACAGTGATGAACACCACCACG-3′)/
cLMPXb for the N-TM1234-C mutant. The mutants containing
only one pair of TM domains between normal amino and
carboxy-terminal regions were similarly constructed. The N-
TM12-C mutant was generated by ligation of the fragments
amplified from pCinLMP1 between primers pairs pCi-T7/
LMP7466 and LMP24S/cLMPXb while the N-TM56-C mutant
resulted from ligation of fragments amplified with primers pairs
pCi-T7/LMP2318 and LMP28S/cLMPXb. The N-TM34-C
mutant was obtained in the same way but amplifications were
performed using the N-TM1234-C mutant as template, between
primer pairs pCi-T7/LMP2318 andLMP3AS/cLMPXb. All the
amplifications were performed using the Phusion High-fidelity
DNA polymerase (FINNZYMES) according to manufacturer's
instructions. Constructions were thoroughly verified by DNA
sequencing. The pCin-Luc vector driving luciferase expression
from the IE-CMV promoter was constructed by inserting the
luciferase gene excised from the p-MAM-neo-luciferase vector
(Clontech) with the NheI and XhoI restriction enzymes into the
NheI and SalI sites of pCi-neo. The pEF-Luc vector was
derived from pCin-Luc of which the IE-CMV promoter was
removed by NheI and BglII digestion and replaced by the EF-
1α promoter excised from the pEF-Bos vector (Mizushima and
Nagata, 1990). This vector was digested with the HindIII
enzyme, treated with T4 DNA polymerase, ligated to BamHI
linkers and finally digested with BamHI and XbaI restriction
enzymes. The 1.2 kpB fragment bearing the EF-1α promoter
was then gel purified and cloned into the NheI–BglII digested
pCin-Luc vector. The pSVK3-EGFP plasmid was obtained by
inserting the SmaI–XhoI EGFP fragment isolated from the
pIRES-EGFP vector (Clontech) into the identical sites of the
pSVK3 vector (Pharmacia). The pNF-κB-Luc vector was de-
rived from the pNF-κB-d2EGFP (Clontech) by replacing the
EGFP gene by the luciferase gene from the pMAM-neo-
luciferase vector (Clontech). The XbaI site of pNF-kB-d2EGFP
was transformed in an XhoI site using linkers and the plasmid
was digested with the HindIII and XhoI restriction enzymes
and gel purified.
Similarly, the NheI site of the pMAM-neo-luciferase vector
was replaced by an HindIII site before digestion with the
HindIII and XhoI enzymes. The 1.9 kpB fragment containing
the luciferase gene has then been gel purified and finally
cloned into the HindIII–XhoI-digested pNF-κB plasmid to
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pCin-β Gal vector, the HindIII site of the pSV-β-galactosi-
dase vector (Promega) was first replaced by an NheI site
using linkers. The β-galactosidase containing fragment was
then excised using NheI and XbaI restriction enzymes, gel
purified and ligated into the same sites of the pCi-neo vector.
Correct orientation was verified by restriction mapping and
DNA sequencing, and expression of β-galactosidase was
controlled using the β-galactosidase enzyme assay system
(Promega).
Cell lines, culture and transfections
DG75 is an EBV free established cell line derived from a
Burkitt-like malignant lymphoma (Ben-Bassat et al., 1977).
Cells were cultivated at 37 °C, under 5%CO2, in RPMI1640
supplemented with 3% FBS, antibiotics and sodium pyruvate.
For transfections, DG-75 cells were centrifuged and
resuspended at a concentration of 107 cells/mL in RPMI1640.
One hundred microliters of the cell suspension was mixed with
reporter and/or tested plasmids, and empty vector (pCi-neo)
added to equalize DNA quantities (6 μg per 100 μL cell
suspension). The mixture was transferred in a 2 mm electro-
poration cuvette (Eurogentec) and shocked using a Gene Pulser
II electroporator (BioRad) with the following settings: R = max,
C = 500 μF, V = 150 V. After electroporation, cells were
cultivated in complete medium at 37 °C/5%CO2 for 24 h,
unless otherwise stated.
Analysis of luciferase activity
Transfected cells were prepared according to the Luciferase
Assay System Protocol (Promega) and lysed in 150 μL of 1×
Cell Culture Lysis Reagent (CCLR, Promega). After centrifu-
gation to pellet cellular debris, 20 μL supernatant was
transferred into a 96 well opaque plate. Produced luciferase
was quantified by measuring the light emitted upon injection of
80 μL of luciferin solution (Promega) using a Berthold Mithras
luminometer. In experiments where the results were normalized
according to the fractions of GFP-positive cells, half of the
transfected cells were taken for FACS analysis while the rest
was treated for luciferase assay.
cDNA synthesis and semi-quantitative RT-PCR
DG75 cells were cotransfected as described above with
pSVK3-EGFP and pCin-β gal or pCin-LMP1 plasmids. Forty
hours later, similar amounts of GFP-positive and GFP-
negative cells were sorted on an Epics Altra cell sorter
(Beckman-Coulter). RNA was purified using an RNeasy Mini
Kit (Qiagen), ethanol precipitated and finally resuspended in
RNAse free water (10 μL per 5 104 cells). cDNA synthesis
was performed on 300 ng total RNA after olido-dT
annealing, using the SuperScript Preamplification system
(Gibco). For semi-quantitative RT-PCR, 5 identical tubes for
each cDNA were prepared, containing 0.5 μL cDNA and
19.5 μL of the mixture: 4 μL 5× Polymerase buffer, 0.4 μLof 10 mM dNTP solution, 0.8 μL of each 10 μM primer solution
and 0.1 μL (0.2 units) Phusion DNA polymerase (Finnzymes).
Amplification conditions were 98 °C for 30 s and then 12, 14, 16,
18 and 20 cycles at 98 °C for 12 s, 63 °C (EF-1α) or 65 °C
(GAPDH) for 15 s and 72 °C for 8 s (EF-1 α) or 12 s (GAPDH).
Amplification productswere then analyzed on a 2%agarose gel and
quantified using the Gene Tool software. Primers used for the EF-
1α amplification were EF-E6E7-S (TTCACTGCTCAGGTG-
ATTATCCTGAACC) and EF-E8E7-AS (AACAGCAAAGC-
GACCCAAAGGTGG), and those for GAPDH were GAPDH-S
(ACCACAGTCCATGCCATCAC) and GAPDH-AS
(TCCACCACCCTGTTGCTGTA).
Western blots
CCLR lysates used for luciferase quantification were
diluted with an equal volume of electrophoresis sample
buffer, separated in a 0.1% SDS–12% polyacrylamide gel and
electrophoretically transferred to PVDF membranes (Amer-
sham). Membranes were incubated overnight at 4 °C with
TBS supplemented with 5% nonfat dry milk and 1%Tween-
20. LMP1 was detected by incubating the blots sequentially
with culture supernatants from S12 mAb secreting hybridoma
(diluted 1 in 300) and with the HRP goat anti-mouse IgG
antibody (Dako). Actin was detected with AC-15 anti-β actin
affinity purified mAb (SIGMA) and the same secondary
antibody. PARP isoforms were detected by sequentially
incubating the membranes with the C2-10 anti-PARP
monoclonal antibody (BD Pharmingen) and the HRP-Goat
anti-mouse IgG antibody. Blots were revealed using the
ECLplus detection kit according to manufacturer's instruc-
tions (Amersham) and CL-Xposure films (Pierce).
Flow cytometric analysis
One to five million cells were incubated for 15 min at
37 °C in 1 mL of complete RPMI1640 containing 15 μM of
CMTMR cell tracker orange (Molecular probes), washed,
incubated in 2 mL of complete medium for 30 min at
37 °C, centrifuged and resuspended in FCS-free RPMI1640
medium. Stained cells were immediately mock-electroporated
or electroporated with 2 μg of the indicated vectors and
4 μg of pSVK3-GFP per transfection. Half of the mock-
electroporated cells were cultivated with mitomycin C
(SERVA) at a final concentration of 10 μg/mL. All cells
were finally cultivated in complete medium for 48 h,
harvested and washed in PBS. Fluorescence was immedi-
ately read using a Coulter XL FACS and data were analyzed
using WinMDI software package purchased on the facs.
scripps.edu/software.html web site. Flow cytometric sorting
was performed using an Epics Altra cell sorter (Beckman-
Coulter), on each population of stained and transfected cells,
according to correct size and forward scatters and to their
green fluorescence status. The same amount of GFP-positive
and -negative cells (2 × 105) was sorted from all ex-
periments, recovered in 1 mL FCS and washed twice with
PBS.
392 S. Narbonnet, B. Mariamé / Virology 350 (2006) 381–393Acknowledgments
We thank Claudie Offer and Helene Brun for performing all
the DNA sequencing required to verify our constructions,
Fatima L'Faqihi-Olive for her help in FACS analysis and cell
sorting, Jerome Terrasson and Sophie Allart for their advises in
anti-PARP Western blot experiment, Fabienne Meggetto for the
kind gift of the S12 monoclonal antibody and Eliane Piaggio
and Anne Dejean for their help in CMTMR labeling. We are
also deeply indebted to Sarah Hull who greatly helped to
improve the English version of this paper. SN is a recipient of an
“allocation de recherche du Ministère délégué à la Recherche et
aux nouvelles technologies”.
References
Baichwal, V.R., Sugden, B., 1988. Transformation of Balb 3T3 cells by the
BNLF-1 gene of Epstein–Barr virus. Oncogene 2 (5), 461–467.
Ben-Bassat, H., Goldblum, N., Mitrani, S., Goldblum, T., Yoffey, J.M., Cohen,
M.M., Bentwich, Z., Ramot, B., Klein, E., Klein, G., 1977. Establishment in
continuous culture of a new type of lymphocyte from a “Burkitt like”
malignant lymphoma (line D.G.-75). Int. J. Cancer 19 (1), 27–33.
Chen, H., Hutt-Fletcher, L., Cao, L., Hayward, S.D., 2003. A positive
autoregulatory loop of LMP1 expression and STAT activation in epithelial
cells latently infected with Epstein–Barr virus. J. Virol. 77 (7), 4139–4148.
Coffin III, W.F., Erickson, K.D., Hoedt-Miller, M., Martin, J.M., 2001. The
cytoplasmic amino-terminus of the Latent Membrane Protein-1 of Epstein–
Barr Virus: relationship between transmembrane orientation and effector
functions of the carboxy-terminus and transmembrane domain. Oncogene
20 (38), 5313–5330.
Coffin III, W.F., Geiger, T.R., Martin, J.M., 2003. Transmembrane domains 1
and 2 of the latent membrane protein 1 of Epstein–Barr virus contain a lipid
raft targeting signal and play a critical role in cytostasis. J. Virol. 77 (6),
3749–3758.
Eliopoulos, A.G., Rickinson, A.B., 1998. Epstein–Barr virus: LMP1 masquer-
ades as an active receptor. Curr. Biol. 8 (6), R196–R198.
Eliopoulos, A.G., Young, L.S., 2001. LMP1 structure and signal transduction.
Semin. Cancer Biol. 11 (6), 435–444.
Eliopoulos, A.G., Gallagher, N.J., Blake, S.M., Dawson, C.W., Young, L.S.,
1999. Activation of the p38 mitogen-activated protein kinase pathway by
Epstein–Barr virus-encoded latent membrane protein 1 coregulates
interleukin-6 and interleukin-8 production. J. Biol. Chem. 274 (23),
16085–16096.
Floettmann, J.E., Ward, K., Rickinson, A.B., Rowe, M., 1996. Cytostatic effect
of Epstein–Barr virus latent membrane protein-1 analyzed using tetracy-
cline-regulated expression in B cell lines. Virology 223 (1), 29–40.
Gires, O., Zimber-Strobl, U., Gonnella, R., Ueffing, M., Marschall, G., Zeidler,
R., Pich, D., Hammerschmidt, W., 1997. Latent membrane protein 1 of
Epstein–Barr virus mimics a constitutively active receptor molecule. EMBO
J. 16 (20), 6131–6140.
Gires, O., Kohlhuber, F., Kilger, E., Baumann, M., Kieser, A., Kaiser, C.,
Zeidler, R., Scheffer, B., Ueffing, M., Hammerschmidt, W., 1999. Latent
membrane protein 1 of Epstein–Barr virus interacts with JAK3 and activates
STAT proteins. EMBO J. 18 (11), 3064–3073.
Hammarskjold, M.L., Simurda, M.C., 1992. Epstein–Barr virus latent
membrane protein transactivates the human immunodeficiency virus type
1 long terminal repeat through induction of NF-kappa B activity. J. Virol. 66
(11), 6496–6501.
Hammerschmidt, W., Sugden, B., Baichwal, V.R., 1989. The transforming
domain alone of the latent membrane protein of Epstein–Barr virus is toxic
to cells when expressed at high levels. J. Virol. 63 (6), 2469–2475.
Henderson, S., Rowe, M., Gregory, C., Croom-Carter, D., Wang, F.,
Longnecker, R., Kieff, E., Rickinson, A., 1991. Induction of bcl-2
expression by Epstein–Barr virus latent membrane protein 1 protects
infected B cells from programmed cell death. Cell 65 (7), 1107–1115.Higuchi, M., Izumi, K.M., Kieff, E., 2001. Epstein–Barr virus latent-infection
membrane proteins are palmitoylated and raft-associated: protein 1 binds to
the cytoskeleton through TNF receptor cytoplasmic factors. Proc. Natl.
Acad. Sci. U.S.A. 98 (8), 4675–4680.
Horvai, A.E., Xu, L., Korzus, E., Brard, G., Kalafus, D., Mullen, T.M., Rose,
D.W., Rosenfeld, M.G., Glass, C.K., 1997. Nuclear integration of JAK/
STAT and Ras/AP-1 signaling by CBP and p300. Proc. Natl. Acad. Sci. U.
S.A. 94 (4), 1074–1079.
Kaye, K.M., Izumi, K.M., Kieff, E., 1993. Epstein–Barr virus latent membrane
protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl.
Acad. Sci. U.S.A. 90 (19), 9150–9154.
Kaykas, A., Sugden, B., 2000. The amino-terminus and membrane-spanning
domains of LMP-1 inhibit cell proliferation. Oncogene 19 (11), 1400–1410.
Kieff, E., Rickinson, A., 2001. Epstein–Barr virus and its replication. In: Knipe,
D., Howley, P., Griffin, D., et al. (Eds.), Fields Virol., vol. 2. Lippincott
Williams Wilkins, Philadelphia, pp. 2511–2573.
Kieser, A., Kilger, E., Gires, O., Ueffing, M., Kolch, W., Hammerschmidt, W.,
1997. Epstein–Barr virus latent membrane protein-1 triggers AP-1 activity
via the c-Jun N-terminal kinase cascade. EMBO J. 16 (21), 6478–6485.
Kilger, E., Kieser, A., Baumann, M., Hammerschmidt, W., 1998. Epstein–Barr
virus-mediated B-cell proliferation is dependent upon latent membrane
protein 1, which simulates an activated CD40 receptor. EMBO J. 17 (6),
1700–1709.
Kulwichit, W., Edwards, R.H., Davenport, E.M., Baskar, J.F., Godfrey, V.,
Raab-Traub, N., 1998. Expression of the Epstein–Barr virus latent
membrane protein 1 induces B cell lymphoma in transgenic mice. Proc.
Natl. Acad. Sci. U.S.A. 95 (20), 11963–11968.
Laherty, C.D., Hu, H.M., Opipari, A.W., Wang, F., Dixit, V.M., 1992. The
Epstein–Barr virus LMP1 gene product induces A20 zinc finger protein
expression by activating nuclear factor kappa B. J. Biol. Chem. 267 (34),
24157–24160.
Lam, N., Sugden, B., 2003. CD40 and its viral mimic, LMP1: similar means to
different ends. Cell Signal 15 (1), 9–16.
Lam, N., Sandberg, M.L., Sugden, B., 2004. High physiological levels of LMP1
result in phosphorylation of eIF2 alpha in Epstein–Barr virus-infected cells.
J. Virol. 78 (4), 1657–1664.
Lee, Y., Sohn, W.J., Kim, D.S., Kwon, H.J., 2004. NF-kappaB- and c-Jun-
dependent regulation of human cytomegalovirus immediate-early gene
enhancer/promoter in response to lipopolysaccharide and bacterial CpG-
oligodeoxynucleotides in macrophage cell line RAW 264.7. Eur. J.
Biochem. 271 (6), 1094–1105.
Miller, W.E., Earp, H.S., Raab-Traub, N., 1995. The Epstein–Barr virus latent
membrane protein 1 induces expression of the epidermal growth factor
receptor. J. Virol. 69 (7), 4390–4398.
Mizushima, S., Nagata, S., 1990. pEF-BOS, a powerful mammalian expression
vector. Nucleic Acids Res. 18 (17), 5322.
Murono, S., Inoue, H., Tanabe, T., Joab, I., Yoshizaki, T., Furukawa, M.,
Pagano, J.S., 2001. Induction of cyclooxygenase-2 by Epstein–Barr virus
latent membrane protein 1 is involved in vascular endothelial growth factor
production in nasopharyngeal carcinoma cells. Proc. Natl. Acad. Sci. U.S.A.
98 (12), 6905–6910.
Patel, T., Gores, G.J., Kaufmann, S.H., 1996. The role of proteases during
apoptosis. FASEB J. 10 (5), 587–597.
Puls, A., Eliopoulos, A.G., Nobes, C.D., Bridges, T., Young, L.S., Hall, A.,
1999. Activation of the small GTPase Cdc42 by the inflammatory cytokines
TNF (alpha) and IL-1, and by the Epstein–Barr virus transforming protein
LMP1. J. Cell Sci. 112 (Pt. 17), 2983–2992.
Sandberg, M.L., Kaykas, A., Sugden, B., 2000. Latent membrane protein 1 of
Epstein–Barr virus inhibits as well as stimulates gene expression. J. Virol.
74 (20), 9755–9761.
Sugimoto, M., Tahara, H., Ide, T., Furuichi, Y., 2004. Steps involved in
immortalization and tumorigenesis in human B-lymphoblastoid cell lines
transformed by Epstein–Barr virus. Cancer Res. 64 (10), 3361–3364.
Tabakin-Fix, Y., Huleihel, M., Aboud, M., 2004. Activation of simian virus 40
promoter by HTLV-I Tax protein: role of NF-kappaB and CBP. Biochem.
Biophys. Res. Commun. 318 (4), 1052–1056.
Takeshita, H., Yoshizaki, T., Miller, W.E., Sato, H., Furukawa, M., Pagano, J.S.,
Raab-Traub, N., 1999. Matrix metalloproteinase 9 expression is induced by
393S. Narbonnet, B. Mariamé / Virology 350 (2006) 381–393Epstein–Barr virus latent membrane protein 1 C-terminal activation regions
1 and 2. J. Virol. 73 (7), 5548–5555.
Wakabayashi-Ito, N., Nagata, S., 1994. Characterization of the regulatory
elements in the promoter of the human elongation factor-1 alpha gene.
J. Biol. Chem. 269 (47), 29831–29837.
Wang, D., Liebowitz, D., Kieff, E., 1985. An EBV membrane protein
expressed in immortalized lymphocytes transforms established rodent
cells. Cell 43 (3 Pt. 2), 831–840.
Wang, D., Liebowitz, D., Wang, F., Gregory, C., Rickinson, A., Larson, R.,
Springer, T., Kieff, E., 1988. Epstein–Barr virus latent infection membrane
protein alters the human B-lymphocyte phenotype: deletion of the amino
terminus abolishes activity. J. Virol. 62 (11), 4173–4184.
Wilson, J.B., Weinberg, W., Johnson, R., Yuspa, S., Levine, A.J., 1990.Expression of the BNLF-1 oncogene of Epstein–Barr virus in the skin of
transgenic mice induces hyperplasia and aberrant expression of keratin 6.
Cell 61 (7), 1315–1327.
Yasui, T., Luftig, M., Soni, V., Kieff, E., 2004. Latent infection membrane
protein transmembrane FWLY is critical for intermolecular interaction, raft
localization, and signaling. Proc. Natl. Acad. Sci. U.S.A. 101 (1),
278–283.
Young, L.S., Rickinson, A.B., 2004. Epstein–Barr virus: 40 years on. Nat. Rev.,
Cancer 4 (10), 757–768.
Zhang, Q., Brooks, L., Busson, P., Wang, F., Charron, D., Kieff, E., Rickinson,
A.B., Tursz, T., 1994. Epstein–Barr virus (EBV) latent membrane protein 1
increases HLA class II expression in an EBV-negative B cell line. Eur. J.
Immunol. 24 (6), 1467–1470.
